AstraZeneca’s triple therapy for chronic obstructive pulmonary disease (COPD), Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), has been approved in the US following a re
Teva has launched new digital inhaler and drug combination in the US, containing built-in sensors that connect to a phone to help manage asthma and COPD symptoms.
More than two years after first saying it would take its lead drug into a pivotal trial, Verona Pharma looks like it may finally follow through on that promise.
We speak to Verona Pharma’s CEO Jan-Anders Karlsson to find out how the company is looking to tackle the challenges of COPD, a surprisingly overlooked disease.
AstraZeneca has seen three of its drugs approved by the Japanese regulator – a new indication for its cancer drug Lynparza, and two new combination therapies for patients with chronic obstr